Table 2 MTX-related toxicities and outcome

MTX infusion

 Median dose (g)

7.4 [4.9–14]

5.85 [5.1–10.5]

0.814

 Time since ICU admission (days)

4 [1–7]

4 [2.2–8.7]

0.335

Interacting medications

 Mean number of medications (sd)

0.69 (0.89)

0.8 (0.92)

0.578

  Piperacillin-tazobactam

4

4

  Proton-pump inhibitors

6

3

  Levetiracetam

4

0

MTX-related complications

18 (78%)

9 (90%)

0.76

 Including^a

 Acute kidney injury

7 (30%)

4 (40%)

 Mucositis

15 (65%)

6 (60%)

 Diarrhea

6 (26%)

8 (80%)

 Liver tests disturbances

11 (48%)

4 (40%)

MTX concentrations (µmol/L)

 MTX H24

3.1 [1.5–5.62]

19.5 [6.2–29.4]

0.052

 MTX H36

5.4 [3–7.7]

16.7 [2.23–44.2]

0.643

 MTX H48

0.4 [0.3–0.7]

1.6 [0.6–5.9]

0.103

 MTX H72

0.3 [0.1–0.4]

0.6 [0.2–3.9]

0.143

 MTX H96

0.07 [0.02–0.12]

0.34 [0.26–1.25]

0.013

Specific treatments

 Median dose of folinic acid rescue (mg)

200 [200–200]

320 [200–800]

0.003

 Carboxypeptidase

1 (4.3%)

2 (20%)

0.436

Outcomes

 Length of ICU stay (days)

10 [6–18.5]

19.5 [10.7–25]

0.16

 Length of hospital stay

64.5 [37–103]

36 [29–72.7]

0.13

 End of life decision

2 (9%)

9 (90%)

< 0.001